Drug Approval | April 07, 2024
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
The Product is expected to be the first generic approval on the market
The Product is expected to be the first generic approval on the market
_256_384.jpg)
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Subscribe To Our Newsletter & Stay Updated
